University of Patras
Η λειτουργία του άξονα osteoprotegerin – RANKL σε νεογνά μητέρων με προεκλαμψία πρώιμης έναρξης και συσχέτιση με καρδιαγγειακούς δείκτες
Abstract
dc:descriptionINTRODUCTIONPreeclampsia is a pregnancy multisystem disorder, defined as hypertension (BP> 140/90 mmHg on at least 2 occasions, > 4 hours apart) and proteinuria (> 300 mg/dL/24 h) after 20 weeks of gestation, in a previously normotensive woman. When severe, preeclampsia can result in marked elevations of BP and end organ dysfunction. It is the most common medical complication of pregnancy and is associated with significant maternal morbidity and mortality, accounting for about 50,000 deaths annually.Most theories suggest that it is a cascade triggered by combination of abnormal maternal inflammatory response, endothelial cell activation/damage with deranged haemodynamic milieu, and deranged immunity. The precise trigger that unifies the derranged vascular, immune and inflammatory responses remains to be elucidated An increasing body of evidence suggests that preeclampsia has long-term consequences and is predictive of future CVD. Women with preeclampsia have a 3- to 4-fold increased risk of developing hypertension, a 2-fold risk for ischaemic heart disease, and increased stroke risk compared with women without a history of preeclampsia The offspring of affected pregnancies also have an increased risk of higher BP and almost double the risk of stroke in later life. A number of potential mechanisms for adverse cardiovascular programming in offspring exposed to preeclampsia have been proposed, considering two major areas of investigation: experimental animal models and offspring cardiovascular phenotype in humans .Preeclampsia can be classified into 2 different entities, early and late-onset preeclampsia. Early-onset preeclampsia is diagnosed before 34 weeks of gestation and carries the greatest risk of long-term cardiovascular sequelae. These observations raise the possibility that mothers develop early onset disease, because they have underlying physiological or biological differences that persist beyond pregnancy and may be transferred between generations. Therefore, early-onset disease may have different implications for cardiovascular risk in the offspring (early-onset or more easily detectable abnormalities) .Understanding the pathophysiology and improving the clinical management of cardiovascular disease involves knowledge of novel risk factors and biomarkers. The clinical and mechanistic roles of these novel biological factors during childhood are currently being investigated .There is emerging evidence that OPG participates in the pathogenesis of atherosclerosis and cardiovascular diseases by amplifying the adverse effects of inflammation and several traditional risk factor. Some epidemiological studies also showed a positive association between OPG levels and cardiovascular morbidity and mortality . This cytokine pathway has three major components: the receptor activator of nuclear factor kB (RANK), its ligand RANKL and osteoprotegerin (OPG) and plays an important role in bone resorption and vascular calcification . OPG protects endothelial vascular cells from apoptosis and prevents the osteogenic differentiation of the vascular smooth muscle cells, which represents a key event in arterial calcification and atherosclerosis . There are data suggesting that OPG gene variants may be associated with early-onset severe pre-eclampsia . Also, OPG protein and mRNA level in placentas of preeclampsia were found abnormal compared with normal pregnancy and were closely related with its important clinical parameters implying that OPG might be closely correlated with the pathogenesis of preeclampsia . However, there is paucity of data concerning the function of OPG-RANKL axis in neonates of mothers with preeclampsia.HYPOTHESISAs early-onset preeclampsia represents a different subclass of the disorder, which is associated with serious complications and long-term sequelae, we hypothesised that an altered cardiovascular profile with detectable abnormalities may already be present in the neonatal period.The primary aim of the present study is to investigate if early-onset preeclampsia affects the function of OPG and RANKL serum levels in premature neonates.The secondary aim is to investigate the possible association between OPG levels, aortic intima-media thickness (aIMT) and non-invasive BP in the same polulation.PATIENTSCase-control study of Neonates admitted in the NICU. Patients: neonates of mothers with early onset preeclampsia fulfilling the diagnostic criteria of the ACOG (1) Controls: neonates of normotensive mothers matched for gender, gestational age and twinning. METHODS1.Quantitative determination of RANKL and OPG in serum on the second and fifth day of life with enzyme immunoassay (Biomedica Medizinprodukte GmbH & Co KG, Austria)2.Total calcium, magnesium, phosphorus and alkaline phosphatase will be determined in serum with an AU640TM Chemistry Immunoanalyser (Olympus America Inc.)3.Aortic intima-media thickness (aIMT) will be measured in the distal abdominal aorta using a linear array probe, and adjusted for aortic lumen diameter on the second and fifth day of life .4.BP will be measured in the right upper arm with an oscillometric monitor at birth, on the second and fifth day of life SIGNIFICANCE OF THE STUDYThere is current evidence suggesting long-term cardiovascular morbidity in mothers with preeclampsia as well as data supporting adverse cardiovascular programming in the offspring. The fact that children and adults exposed to early-onset preeclampsia can be easily identified based on precise clinical criteria in their mother, raises the possibility for novel, targeted, primary prevention strategies for cardiovascular risk reduction in a high risk group within the community.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Oikonomou, Nikoleta
- Οικονόμου, Νικολέτα
Subjects
dc:subject × 16- Προεκλαμψία πρώϊμης έναρξης
- Προωρότητα
- Οστεοπροτεγερίνη (OPG)
- Μόριο-πρόσδεμα TRAIL
- Νεογνό
- Preeclampsia
- Prematurity
- Osteoprotegerin (OPG)
- Trail
- Neonates
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Παιδιατρική, Νεογνολογία και Υγεία του παιδιού
- Clinical Medicine
- Medical and Health Sciences
- Pediatrics, Perinatology and Child Health
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51142